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Abstract Bear bile has been included in Asian pharmaco-
peias for thousands of years in treatment of several
diseases, ranging from sore throat to hemorrhoids. The
hydrophilic bile acids tauroursodeoxycholic acid (TUDCA)
and ursodeoxycholic acid (UDCA) are the major bile acids
of bear bile. Both of these are available as synthetic
formulations and are approved by the health administrations
of several countries for treatment of cirrhosis and gall-
stones. This review briefly covers the use of bear bile in
Traditional Chinese Medicine, bile acid physiology, ap-
proved use of UDCA and TUDCA in Western medicine,
and recent research exploring their neuroprotective proper-
ties, including in models of ocular disease.
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Bear bile use in traditional Chinese medicine
Bear bile, bile extract, and gallbladder have been used in
Traditional Chinese Medicine (TCM) and other Asian
pharmacopeia for thousands of years [1–3]. Bear bile is
classified as a “cold” medicine used to treat diseases of
“heat” that involve fevers and inflammation to detoxify the
liver, to prevent convulsions and epileptic seizures, to
dissolve kidney stones and gallstones, to shrink tumors and
hemorrhoids, and to improve vision [1–3]. Its use continues
in TCM and has spread with the establishment of Asian
communities throughout the world [3]. China’s State
Pharmacopoeia lists 28 types of medicines containing bear
bile, 15 of which are used in ophthalmology [4].
The Asian black bear (Ursus thibetanus or Selenarctos
thibetanus), also known as the Moon bear due to its coat
markings, is the traditional source species, but as Moon
bear populations decline, other species such as the North
American black bear are used, often with negative
consequences on those populations [5]. To address the
issue of declining populations and in recognizing that
trafficking in animal parts is a component of their rural
economy (dried bear bile has a higher street value than
cocaine [6]), controlled bear farming was established in
China [2–4]. However, the harvesting of bear parts is
considered by many to be cruel [4, 7], and it is illegal or
greatly restricted in many countries [3–6] (particularly the
signatory nations of the Convention on International Trade
in Endangered Species of Wild Fauna and Flora [8] and
additionally in the USA by the Endangered Species Act
[9]), and it is not clear that the farming is sustainable
economically or politically [4, 7, 10]. Thus, there is great
interest in replacing bear parts with herbal and synthetic
substitutes in TCM [3, 4].
Bile acid physiology
Bile acids are biosynthesized from cholesterol in liver
hepatocytes. They are largely contained in the enterohepatic
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DOI 10.1007/s12177-009-9030-xcirculation and are stored in the gallbladder. They are
predominantly conjugated with glycine or taurine, allowing
them to be fully ionized in the pH range of the small
intestine [11]. Bile acids have five major functions:
elimination of cholesterol, micellination of dietary lipids
to aid in their transport, stimulation of bile flow and biliary
phospholipid secretion, and finally, negative feedback
regulation of bile acid and cholesterol synthesis [11].
In humans, the principle primary bile acids are cholic
acid and chenodeoxycholic acid (CDCA) and the principle
secondary bile acids are deoxycholic acid (DCA) and
lithocholic acid. Conversely, the biliary bile and the serum
of some bears contain high proportions of ursodeoxycholic
acid (UDCA), mainly occurring as its taurine conjugate
tauroursodeoxycholic acid (TUDCA) [12–15]. UDCA and
conjugates comprise about 47% of the biliary bile make up
in American black bear and up to 76% in Asiatic black bear
[13]. UDCA and TUDCA are found only in trace amounts
(<1–5% of total biliary bile acid composition) in other
vertebrates [13]. Similar to biliary bile content, the taurine-
conjugated form of UDCA comprises a large proportion
(about 28%) of the circulating plasma levels of bile acids in
American black bears [14]. In comparison, TUDCA
constitutes about 0.13% of the bile acid pool in human
serum [16]. As UDCA and TUDCA are the major
constituents of bile from Asian black bears, these two
hydrophilic bile acids have long been considered by many
to be the bioactive components of bear bile [3, 4, 7, 10, 14].
Synthetic UDCA and TUDCA as therapeutics
UDCA and TUDCAwere first synthesized from cholic acid
in 1954 in Japan [17]. Today UDCA is produced by several
manufacturers worldwide and marketed under various trade
names, including Ursodiol, Actigall, Ursosan, Urso, Urso
Forte, and Deursil. UDCA is approved by several govern-
ments for treatment of liver diseases and for the dissolution
of gallstones. In Italy, TUDCA is marketed as Taurolite and
is used similarly. Typical oral dosing of UDCA is 7–15 mg/
kg body weight daily. Both TUDCA and UDCA are well
tolerated; the most common side effect is diarrhea in less
than 2% of several populations tested [18–20].
Oral administration of UDCA results in UDCA and its
conjugates becoming the proportionately dominant bile
acids in biliary bile, and serum and plasma absolute
concentrations increase over tenfold [21–26]. About half
of the dose is absorbed from the portal blood into liver via
first pass extraction, where it is conjugated with glycine
forming glycoursodeoxycholic acid (GUDCA) or taurine
forming TUDCA [24, 27–29]. The percentage absorbed
decreases with increasing dose such that absolute and
proportional enrichment of the biliary bile with UDCA and
conjugates plateaus at an as-yet undefined dose due to
epimerization of UDCA to CDCA and endogenous bile
acid synthesis [23, 27, 30, 31]. UDCA and conjugates are
excreted from the biliary tree and resorbed through the
enterohepatic circulation or metabolized to insoluble salts
and excreted in the feces [24]. Oral dosing with TUDCA
produces similar changes in biliary bile acid composition
and circulating bile acid composition and concentrations,
but with higher proportions and concentrations of UDCA
and conjugates, possibly due to reduced intestinal biotrans-
formation of TUDCA, suggesting moderately enhanced
bioavailability [18, 32].
The initial use of UDCA was for dissolution of gall-
stones; it dissolves gallstones by solubilizing cholesterol
from the stone surface, and it reduces the saturation of
cholesterol in the bile, enhancing cholesterol transport [24,
26, 33]. UDCA is still prescribed for gallstone dissolution
in patients who cannot or do not want to undergo surgery
[24, 27, 29].
The other major, institutionally approved use of UDCA
or TUDCA is in treatment of cholestatic liver disease,
especially primary biliary cirrhosis (PBC). The first report
of the use of UDCA or TUDCA in treatment of liver
diseases in Japanese patients came shortly after their
laboratory synthesis was developed in the mid-1950s [24,
29, 34]. However, their use in treatment of liver disease
increased greatly after it was fortuitously discovered that
serum aminotransferase levels improved in patients with
chronic active hepatitis who were receiving UDCA for
gallstone dissolution [24, 35], a discovery that sparked a
series of studies examining its efficacy in treatment of
cholestatic liver disease [11, 24].
UDCA and TUDCA as antiapoptotic cytoprotectants
TUDCA and UDCA were originally thought to act largely
through displacement of hepatotoxic, hydrophobic bile
acids such as CDCA and DCA from the bile acid pool,
thus preventing accumulation of toxic levels in enter-
ohepatic circulation and so reducing the detergent proper-
ties of bile at the hepatocellular membrane [11, 24].
However, two groups nearly simultaneously discovered
that UDCA may have more mechanistic actions than simply
replacing toxic bile acids. Koga et al. [36] found that biliary
epithelial cells (BECs) from PBC patient biopsy tissue had
much less DNA fragmentation from patients treated with
UDCA than from untreated patients, suggesting that BECs
from treated patients undergo less apoptosis than those
from untreated patients.
Rodrigues et al. [37] more directly tested for an
antiapoptotic mechanism. They isolated mitochondria from
rat liver and treated them with UDCA or DCA, a
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increased mitochondrial swelling, calcein release, and
reactive oxygen species (ROS) production, and decreased
the mitochondrial membrane potential. UDCA treatment
inhibited these effects. In the same study, they found that
rats fed with high DCA diets had high concentrations of
Bax protein in their mitochondria, an effect blocked by
adding UDCA to their drinking water. This same group
then demonstrated that UDCA treatment inhibited apoptosis
induced by deoxycholic acid, okadaic acid, and trans-
forming growth factor beta1 in rat hepatocytes in primary
culture [38]. They found that incubation with UDCA
prevented cyctochrome c release, caspase activation, and
cleavage of poly(ADP-ribose) polymerase. They also found
that the apoptosis-inducing agents decreased mitochondrial
transmembrane potential (MTP) and increased Bax translo-
cation from the cytosol to the mitochondrial membrane,
effects blocked by UDCA. From these combined studies,
the authors concluded that UDCA treatment can directly
inhibit changes in MTP and ROS production, thus prevent-
ing megapore opening, membrane potential transition, and
subsequent initiation of an apoptotic cascade [37, 38].
In later experiments, the same group found that exposing
isolated mitochondria to purified, recombinant Bax protein
induced cyctochrome c release without permeability
changes that result in mitochondrial swelling, that is,
independently of the permeability transition pore opening.
This effect in isolated mitochondria was prevented by co-
or pre-incubation with TUDCA. Pre-incubating mitochon-
dria with TUDCA, then washing out the media and
replacing with fresh, produced the same results, indicating
that the effect of TUDCA is not due to direct interaction
between TUDCA and Bax protein in the incubation media
[39]. Thus, both UDCA and TUDCA have antiapoptotic
effects on isolated mitochondria.
More recently, this group and others [40, 41] have
demonstrated that in addition to effects at the mitochondrial
membrane, UDCA and TUDCA may have antiapoptotic
effects by binding or otherwise activating nuclear steroid
receptors. Following nuclear translocation, the hydrophilic
bile acids appear to modulate the E2F-1/p53/Bax pathway
as part of their antiapoptotic mechanism of action (reviewed
in [42, 43]).
UDCA and TUDCA as neuroprotectants
Steer, Rodrigues, Kren, Low, and colleagues extended their
studies in liver disease models to test the effects of UDCA
or TUDCA treatment in models of neuronal disease and
injury. Treatment of rat striatum in vivo or neuronal cells in
culture with 3-nitropropionic acid (3-NP), an irreversible
inhibitor of succinate dehydrogenase, induces apoptosis and
is considered a model of Huntington’s disease (HD). Co-
incubation of an immortalized rat neuronal cell line or rat
striatal cells in primary culture with TUDCA, UDCA, or
GUDCA prevented 3-NP-induced apoptotic events such as
MTP depolarization, mitochondrial-associated Bax translo-
cation, and mitochondrial release of cytochrome c [44, 45].
Intraperotineal injection of rats with 3-NP caused loss of
striatal volume, mitochondrial swelling, increased TUNEL
signal in striatal tissue sections, and Rota-Rod sensorimotor
task and cognitive testing deficits [45]. All of these 3-NP-
induced effects were largely or completely prevented for up
to 6 months if TUDCA was co-administered with the
neurotoxin [45]. The authors tested whether TUDCA is also
neuroprotective in a genetic model of HD. R6/2 mice that
are transgenic for a causative CAG/polyglutamine repeat
expansion of the human HD gene develop striatal intra-
nuclear inclusions containing the proteins huntingtin and
ubiquitin [46] followed by progressive neurological deficits
similar to those of HD [47]. IP injections of TUDCA
starting at 6 weeks of age reduced striatal atrophy,
decreased striatal apoptosis, resulted in fewer and smaller
ubiquitinated neuronal intranuclear huntingtin inclusions,
and improved locomotor and sensorimotor performance
[45]. Thus, systemic TUDCA treatment was found to be
protective and antiapoptotic in cultured cells and in vivo in
acute models and genetic models of HD.
Similarly, using in vivo cell culture and in vitro
approaches, the same core group and colleagues found that
treatment with UDCA or TUDCA slowed cell death in
several neuronal disease models, including Alzheimer’s
disease [48–54], Parkinson’s disease [55], acute hemor-
rhagic [56] and acute ischemic stroke [57], and neuronal
glutamate toxicity [58].
Other laboratories have found that UDCA and TUDCA
are protective in models of neuronal damage or degenera-
tion. For example, incubation with UDCA prevents
apoptosis in a model of cisplatin-induced sensory neurop-
athy, possibly by suppressing p53 accumulation [59]. In an
in vivo spinal cord injury model, rats injected systemically
with TUDCA showed fewer apoptotic cord cells, less tissue
injury, and better hind limb function than untreated control
animals [60]. Related, though not neuronal, UDCA and
TUDCA are antiapoptotic cytoprotectants in ischemia/
reperfusion and oxidative stress models of liver disease or
injury [61–71] and models of heart disease [72–75].
TUDCA as protectant in ocular models
Genetic models of photoreceptor degeneration
G i v e nt h ee f f e c t sd e m o n s t r a t e di ns e v e r a lm o d e l so f
neurodegeneration, it was an obvious strategy to test
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various retinal degeneration models. In our initial experi-
ments, we treated Pde6b
rd1 (rd1) mice with subcutaneous
injections of TUDCA in the same dosing regimen as
was done with the rodent neurodegeneration models
(e.g., 500 mg/kg body weight every 3 days). Injections
started at postnatal day (P) 9 and continued to P21, at
which point animals were killed and retinal cryosections
w e r em a d e .A ss h o w ni nF i g .1, vehicle-treated retinas
showed the expected near-total loss of outer nuclear layer
cells. Conversely, TUDCA-treated retinas had varied
morphology, ranging from very little outer nuclear layer
(ONL) to thick ONL and in some instances the preserva-
tion of what appear to be photoreceptor outer segments.
The response to TUDCA treatment varied greatly.
TUDCA treatment occasionally resulted in enhanced a-
and b-wave electroretinography (ERG) amplitudes, and
morphological changes were only moderately more con-
sistent. This variability was resolved by starting TUDCA
injections of rd1 pups earlier (P6) and with daily injections
rather than every 3 days [76].
Degeneration of photoreceptors begins by at least P8 in
rd1 mice [77], so treatments in our early experiments
possibly started too late to provide consistent protection. To
address this, we chose to treat another mouse model, the
Pde6b
rd10 (rd10) mouse, which became available about the
time we were testing treatment in the rd1 mouse [78]. In
this mouse, a missense mutation in PDE6B causes
degeneration of rods starting at about P14–16 [79, 80].
ERG amplitudes are large enough to be easily measured
through the first month of age, but are never normal, as
would be expected in mice harboring a mutation in a visual
cycle gene [78]. Systemic TUDCA injections of these mice
suppressed apoptosis and greatly slowed loss of photore-
ceptor number, morphology, and function [81, 82]. In rd10
mice at P18, ONL thickness and nuclei counts are about
50% of wild type, photoreceptor outer segments are largely
degenerated, and ERG a- and b-wave amplitudes about
50% of wild type [80]. In P18 rd10 mice, subcutaneous
injections with TUDCA resulted in the preservation of the
number of photoreceptor cells (Fig. 2), ONL thickness,
photoreceptor outer segments (Fig. 3), and ERG a- and b-
Fig. 1 Photomicrographs of ret-
inal cryosections from TUDCA-
treated rd1 mice. Pde6b
rd1 (rd1)
mice were subcutaneously
injected with vehicle or TUDCA
(500 mg/kg body weight every
3 days). Injections started at
postnatal day (P) 9 and contin-
ued to P21, at which point
animals were killed, and retinal
paraffin sections were cut and
stained with hematoxylin and
eosin (H&E-stained). Vehicle-
treated retinas showed the
expected near-total loss of ONL
cells. Conversely, TUDCA-
treated retinas had varied, but
more organized morphology
ranging from very little ONL to
thick ONL and in some instan-
ces the preservation of what
appear to be photoreceptor outer
segments. RPE: retinal pigment
epithelium; IS/OS: inner seg-
ment/outer segment; ONL: outer
nuclear layer; OPL: outer
plexiform layer; INL: inner
nuclear layer; IPL: inner
plexiform layer; GCL: ganglion
cell layer
152 j ocul biol dis inform (2009) 2:149–159wave amplitudes (Fig. 4 and [81]). Retina sections from
mice treated with TUDCA showed almost no TUNEL
signal (Fig. 3) and substantially reduced immunosignal for
activated caspase 3 (Fig. 5), suggesting that treatment
resulted in suppression of apoptosis [81].
Fig. 2 Effect of TUDCA treatment on number of photoreceptor cells
in P18 and P30 rd10 mice. rd10 were injected subcutaneously with
vehicle or TUDCA (500 mg/kg) every 3 days starting at P6. At P18
and P30 mice were killed, and retinal paraffin sections were prepared
and H&E-stained. Outer nuclear layer nuclei were counted in two
regions per section and were assumed to reflect number of
photoreceptor cells. Each region spanned 400µm starting from a
point 400µm from either side of the optic nerve. TUDCA treatment
significantly preserved the number of photoreceptors at both postnatal
days. Of note is that TUDCA treatment delayed the loss of
photoreceptor cells by 12 days over the course of the degeneration
to P30
Fig. 3 Effect of TUDCA treatment on retinal morphology and
TUNEL in P18 rd10 mice. Fluorescence microscopy using a B-2A
emission fluorescence filter allows observation of the preservation of
photoreceptor inner segments (IS) and outer segments (OS) present in
TUDCA- (right) versus vehicle-treated retina sections (left). TUNEL-
positive nuclei (green/yellow signal) are seen to be abundant in
vehicle-treated sections, but rare retinas from TUDCA-treated mice.
TUDCA treatment provided significant preservation of photoreceptor
nuclei number in the outer nuclear layer (ONL). Treatment had no
discernable effect on the inner nuclear layer (INL) or ganglion cell
layer (GCL). Image reprinted with permission from Ref. [81]
Fig. 4 Effect of TUDCA treatment on electroretinograms of rd10
mice at P18 and P30. Representative dark-adapted ERG waveforms
(top) and average b-wave amplitude (bottom) to a bright flash (2.1 log
cd s/m
2) at P18 and P30 in TUDCA and vehicle-treated rd10 mice.
Note that TUDCA treatment delayed the loss of retinal function by
about 12 days, or about 35%, over the course of the degeneration
period (e.g., P30 TUDCA-treated amplitudes are similar to P18
vehicle-treated amplitudes)
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rd10 mouse retina to at least P30. At this stage, the ONL
has degenerated to about one cell layer of mainly cones
(rods are nearly completely absent and cones are degener-
ating), and the dark-adapted a-wave is only 3% and the b-
wave only 14% of wild-type mice [80, 82]. TUDCA-treated
retinas had dark-adapted a-waves that were maintained to
30% of wild-type and light- and dark-adapted b-waves
maintained to 45% of wild-type, indicating preservation of
both rod and cone function (Fig. 4 and [82]). The number
of photoreceptor nuclei was fivefold greater in TUDCA-
treated mice than in vehicle-treated mice (Figs. 2 and 6). Of
Fig. 5 Effect of TUDCA on
caspase-3 activation in rd10
mouse retina. Paraffin-
embedded rd10 mouse retina
sections from mice treated with
vehicle or TUDCAwere assayed
for immunoreactivity to activat-
ed caspase-3 and observed by
confocal microscopy. There was
significantly more immunoreac-
tivity (yellow signal) in vehicle-
treated sections than in
TUDCA-treated sections. Image
reprinted with permission from
Ref. [81]
Fig. 6 Effect of TUDCA treatment on retinal morphology in rd10 and
wild-type mice at P30. Retinal micrographs from P30 wild-type
C57BL/6 mice treated with TUDCA (a) or vehicle (b) and from rd10
mice treated with TUDCA (c) or vehicle (d). TUDCA treatment has
no effect on wild-type retinal morphology. In rd10 mice, the
photoreceptor layer has been reduced to approximately one row of
nuclei (d), but TUDCA treatment preserved three to four rows of
nuclei (c). c and d Clear differences in the thicknesses of the ONL,
outer segments (OS), and inner segments (IS), with TUDCA treatment
demonstrating a delay of retinal degeneration. e and f Plots of the total
number of photoreceptors at each retinal location from wild type and
rd10 mice with reference to the optic nerve head (ONH). The inset is a
diagram of the retina and optic nerve and the areas from which cells
numbers were sampled. The TUDCA-treated mice have significantly
more photoreceptors across all areas sampled than vehicle-treated
mice. Image reprinted from Ref. [82]
154 j ocul biol dis inform (2009) 2:149–159note is that TUDCA treatment delayed the loss of
photoreceptor cell number and retinal function by 12 days
over the course of the degeneration to P30 (Figs. 2 and 4).
Similar to the effect on rod photoreceptors at P18, treatment
preserved cone outer segment morphology in the P30 retina
[82].
Other researchers have tested the effects of TUDCA in
retinal degeneration models. TUDCA treatment slows
retinal degeneration in s334ter-3 rats [83], a rat line that
was genetically engineered to have a rhodopsin mutation
identical to one common in autosomal dominant retinitis
pigmentosa (ADRP) patients [84]. These rats were injected
daily from birth with TUDCA. Retinal sections from P5
and P10 rats showed that TUDCA treatment significantly
decreased markers for reactive oxygen species, endoplas-
mic reticulum (ER) stress, and apoptosis. Retinal degener-
ation as assessed by morphology was also delayed in
TUDCA-treated rats [83].
TUDCA treatment also slows retinal degeneration in
P23H-3 rats [85, 86], another rat line that was genetically
engineered to have an ADRP rhodopsin mutation [84]. Rats
were injected intraperitoneally (500 mg/kg body weight)
once per week from P20 through 4 months old. In TUDCA-
versus vehicle-treated rats, photoreceptor inner and outer
segments, nuclei counts in the ONL, and the capillary
retinal network were preserved. TUNEL signal was lower
in TUDCA-treated rats compared to controls.
Induced models of photoreceptor degeneration
We also tested the effects of TUDCA treatment in mice and
rats undergoing light-induced retinal degeneration (LIRD),
an environmental model of blindness [87, 88]. Adult albino
BALB/C mice were subcutaneously injected with TUDCA
or vehicle, dark-adapted for 18 h, injected again, then
exposed to 7 h of bright (10,000 lx) or dim (200 lx) light
[87], then returned to regular rearing lighting conditions. At
various times post-exposure, ERGs, retinal morphology,
and apoptosis markers were assessed. Within 24 h of
damaging light exposure, there was massive disruption of
photoreceptor cells, extreme disorganization, and heavy
TUNEL signal throughout the ONL in vehicle-treated mice
exposed to bright light (Fig. 7). Conversely, retinas from
TUDCA-treated mice exposed to bright light had low
TUNEL signal and unaltered retinal morphology (Fig. 7),
similar to mice exposed to dim light. Immunoreactivity for
activated caspase-3 was abundant in retina sections from
vehicle-injected mice, but nearly nonexistent in sections
from TUDCA-injected mice exposed to bright light or mice
exposed to dim light (Fig. 8). Protection against light
damage was observed at 15 days post-exposure, again, with
suppression of TUNEL (Fig. 9) and diminished immuno-
signal for activated caspase 3 [81]. ERG amplitudes were
maintained in TUDCA-treated mice exposed to bright light,
even up to 7 weeks post-exposure [89], suggesting that
protection is fairly long term. Thus, in both the rd10 mouse
and the LIRD mouse and rat, apoptotic photoreceptor
degeneration was greatly diminished and retinal function
was largely preserved by systemic injections of TUDCA.
Ganglion cell death model
We also found that systemic TUDCA treatment slowed loss
of retinal ganglion cells following optic nerve crush. Adult
C57/Bl6 mice were treated as in the LIRD and rd10 mouse
experiments for 10 days and anesthetized, and their optic
nerves were transected [90, 91]. In some mice, a gelfoam
sponge soaked in 3% Fluorogold was applied to the cut
optic nerve stumps. Ten days after surgery, the number of
fluorescing RGC somas seen in retina flatmounts declined
by about 60% in vehicle-treated animals, a loss that was
completely prevented in TUDCA-treated mice [90].
Lens models
Thus, systemic treatment with TUDCA slows retinal
degeneration in mouse and rat models, but it also has
effects in other ocular tissues. Shinohara and colleagues
report that TUDCA treatment prevents lens epithelial cell
(LEC) death and cataract formation [92]. Incubating
Fig. 7 Effect of TUDCA on LIRD mouse retina morphology and
apoptosis: 24-h post-light exposure. Mice were subcutaneously
injected with either vehicle or TUDCA (500 mg/kg), exposed to
10,000 lx of white light for 7 h, then returned to maintenance lighting
conditions. Mice were killed 24 h later, and paraffin retina sections
were prepared and assayed for fluorescent TUNEL by confocal
microscopy. Representative composite confocal micrographs for
vehicle (left) versus TUDCA (right) treatments are shown. Bright-
light-exposure-induced massive apoptosis (yellow signal) and mor-
phological damage in photoreceptor cells and retinal outer nuclear
layer of vehicle- (left) but not TUDCA-treated eyes (right). Image
reprinted with permission from Ref. [81]
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mycin induces ER stress and eventually death. However,
pre- and co-incubation with TUDCA prevents this, even
to a greater degree than treatment with the ER stress
chaperones 4-phenylbutyric acid, trimethylamine N-
oxide. Further, systemic injections of TUDCA significant-
ly reduced lens epithelial cell death and partially delayed
hypermature cataract formation in galactosemic rats, an
effect accompanied by suppression of ER stress markers
[92]. Though others have reported that UDCA and
TUDCA efficacy is mediated through alleviation of ER
stress [93–96], only Shinohara and colleagues have
demonstrated that TUDCA acts as a chemical ER stress
chaperone [83, 97].
Fig. 9 Effect of TUDCA on LIRD mouse retina morphology and
apoptosis: 15 days post-light exposure. Mice were subcutaneously
injected with either vehicle or TUDCA (500 mg/kg), exposed to
10,000 lx of white light for 7 h, then returned to maintenance lighting
conditions. Fifteen days after light exposure, mice were killed, and
paraffin retina sections were prepared and assayed for fluorescent
TUNEL by confocal microscopy. Bright-light-exposure-induced mas-
sive apoptosis and morphological damage in retinal photoreceptors of
vehicle-treated (left) but not TUDCA-treated eyes (right). Of
particular note in the vehicle-treated sample is the thinning of the
outer nuclear layer (ONL) and the nearly complete loss of inner
segments (IS) and outer segments (OS) of the photoreceptors.
Additionally, nearly all the photoreceptor nuclei are TUNEL positive.
Conversely, TUDCA-treated samples showed intact photoreceptors,
thick ONL, and very few TUNEL-positive photoreceptor cells.
Treatment had no discernable effect on the inner nuclear layer (INL),
ganglion cell layer (GCL), or retinal pigment epithelium (RPE). Image
reprinted with permission from Ref. [81]
Fig. 8 Effect of TUDCA on LIRD mouse retina caspase-3 activation.
Mice were subcutaneously injected with either vehicle or TUDCA
(500 mg/kg), exposed to 200 (dim) or 10,000 lx (bright) of white light
for 7 h, then returned to maintenance lighting conditions. Mice were
killed 24 h later, and paraffin retina sections were prepared and probed
for activated caspase 3 immunoreactivity by fluorescent confocal
microscopy. Representative composite confocal micrographs for
vehicle dim-light-exposed vehicle-injected (left), bright-light-exposed
vehicle-injected, and bright-light exposed TUDCA-injected (right)
treatments are shown. There was significantly more immunoreactivity
(yellow signal) in sections of bright-light-exposed vehicle-treated mice
than in bright-light-exposed TUDCA-treated mice or dim-light-
exposed mice. Image reprinted with permission from Ref. [81]
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The hydrophilic bile acids UDCA and TUDCA are
cytoprotective in many disease models. Their exact mech-
anisms of action at the molecular level are not fully
elucidated. Their cytoprotective actions are proposed to be
mediated through actions at several points of the intrinsic
and extrinsic apoptotic pathways and the ER stress response
[42, 43, 92, 96, 98] from direct actions on mitochondrial and
ER membranes through transcriptional regulation of both
death and survival factors. Effects in ocular disease models
have just begun to be tested and are clearly promising.
However, almost no mechanistic data from ocular models
have been reported. Indeed, some of the protective effects of
TUDCA may be due to its taurine moiety suppressing
formation of the apoptosome [99, 100]! Thus, in addition to
continued preclinical testing for translational purposes, much
work remains in determining how the hydrophilic bile acids
have such marked protective effects in models of retinal
degeneration, glaucoma, and cataract.
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